Cancer Type: Thoracic
Study Type: Treatment
NCT#: NCT04610658
Phase: Phase I/II
Principal Investigator: Chiappori, Alberto
Activity and Enhancement of Immune Checkpoint Inhibition with Lurbinectedin in Relapsed/Recurrent Small Cell Lung Cancer (SCLC)
This is a single-arm, phase I/II trial to determine the Maximum Tolerated Dose (MTD), Recommended Phase II Dose (RP2D), and the safety and efficacy of the combination of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent small cell lung cancer after progression with first-line, platinum-based chemotherapy
Primary Objective Phase I (Dose Escalation): To determine the MTD and RP2D of nivolumab-ipilimumab plus lurbinectedin. Primary Objective Phase II (Single Arm Cohort): To determine the efficacy of nivolumab-ipilimumab plus lurbinectedin in patients with relapsed/recurrent SCLC. Secondary Objectives: To further describe efficacy and to further describe safety. Tertiary/Exploratory Objectives: To examine potential predictive markers in the turmors of clinical responders. Characterize the evolution of the immune compartment during treatment. Determine Th1, Th2, and Th17 polarization during treatment with ipilimumab-nivolumab plus lurbinectedin.
Chemotherapy (NOS); Immunotherapy
BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); PM01183 (lurbinectedin); Yervoy (Ipilimumab); lurbinectedin ()
Inclusion Criteria:
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday